Sign In
Buy TRML
$47.98
+0 (+0%)
At Close: Jan 27, 2026
Tourmaline Bio to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
08:00am, Thursday, 01'st Feb 2024
NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve t
NEW YORK, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically impr
Tourmaline Bio Announces Pricing of Public Offering of Common Stock
07:00am, Thursday, 25'th Jan 2024
NEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically impr
Tourmaline Bio Announces Proposed Public Offering of Common Stock
04:05pm, Wednesday, 24'th Jan 2024
NEW YORK, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically impr
Tourmaline plans to accelerate the initiation of a pivotal Phase 3 trial in 2024 evaluating subcutaneous TOUR006 every 8 weeks as first-line treatment for TED, with topline data expected in 2026
Tourmaline Bio added to the NASDAQ Biotechnology Index
04:00pm, Friday, 15'th Dec 2023
NEW YORK, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically impr
Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board
07:30am, Thursday, 14'th Dec 2023
NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically impr
Tourmaline Bio: TED And ASCVD Targeting With Differentiated IL-6
02:09pm, Wednesday, 01'st Nov 2023
Tourmaline Bio is advancing the use of its drug candidate TOUR006 for the treatment of thyroid eye disease and atherosclerotic cardiovascular disease. The ongoing phase 2b spiriTED study, which is usi
Tourmaline Bio to Present at Upcoming Investor Conferences
08:00am, Wednesday, 01'st Nov 2023
NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of pa
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
05:37pm, Thursday, 19'th Oct 2023
Tourmaline will be focused on advancing TOUR006, its differentiated anti-IL-6 antibody, to treat thyroid eye disease (TED), atherosclerotic cardiovascular disease (ASCVD) and other diseases
